Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Inclusion Criteria: * Adult patients (18th year of age completed) * Signed and dated written informed consent form prior to any procedures related to this protocol. * Histologically confirmed advanced clear cell renal cancer. * Measurable disease. * Failure of first line anti-VEGF treatment. * Performance status 0-2, according to Eastern Cooperative Oncology Group (ECOG) . * Satisfactory hematological parameters: * White blood cell count \> 4000 mm3. * Platelet count 100000/mm3. * Neutrophil blood cell count \> 1200/ mm3 . * Hemoglobin \> 9,0 g/dL (can be achieved with red blood cell transfusion). * Satisfactory biochemical parameters: * Serum creatinine \< 2 x Upper Limit of Normal(ULN) * Aspartate Aminotransferase (AST)\<2,5 x ULN * Alanine Transaminase (ALT)\< 2,5 x ULN. * Bilirubin \<2 x ULN * (For female patients) Absence of pregnancy (negative pregnancy test for women of reproductive age before enrollment). * (For female patients) Non-lactating women. * Use of efficient contraceptive measures (women and men) to prevent possible pregnancy of female patient or female partner of a male patient during treatment and until 6 months after the end of treatment. Exclusion Criteria: * Prior treatment with mTOR inhibitor. * Major surgery (including open biopsy) or insufficient recovery or existence of major trauma within 4 weeks before enrollment. * Uncontrolled hypertension. * Active infection requiring systemic treatment within 4 weeks prior to enrollment. * Minor surgery (for instance, catheter placement) within 2 days before enrollment. * Scheduled major surgery within the treatment period. * Medical history in the last 6 months prior to enrollment of significant cardiovascular disease, diabetes, cardiac infarction, unstable angina, uncontrolled arrhythmia or significant heart failure. * Indications of uncontrolled metastases or disease progression in CNS lesions (the suspicion of uncontrolled metastases or disease progression should be eliminated by imaging techniques within 14 days prior to enrollment). * Medical history in the last 5 years prior to enrollment of any other malignancies (excluding the basal or squamous skin cell carcinoma or in situ carcinoma of the cervix). * History of non-healing wound including active gastric ulcer. * History of fistula in the last 6 months prior to enrollment. * History of gastrointestinal perforations. * Patient incapacity (for psychiatric or social reasons) to conform with the protocol. * History of hemorrhagic predisposition. * History of hypersensitivity to the medications under investigation. * Significant proteinurea. * Prior immunotherapy within 4 weeks prior to enrollment. * Prior radiation treatment within 2 weeks prior to enrollment. * Concomitant medication with inducers or strong inhibitors of the coenzyme CYP3A4 (see Appendix 5 for an indicative list of active compounds). * Concurrent participation in other interventional clinical trials with investigational medicinal products. * History of chronic interstitial lung disease.